Expanded Prostate Cancer Index Composite for Clinical Practice Questionnaire

Known as: EPIC-CP, EPIC2 
A standardized rating scale developed by Chang et al in 2011, which is used to measure urinary incontinence, urinary irritation, and the bowel… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2016
0120092016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
PURPOSE EPIC-CP (Expanded Prostate Cancer Index Composite for Clinical Practice) is a short questionnaire that comprehensively… (More)
Is this relevant?
Review
2017
Review
2017
OBJECTIVE To determine the clinical characteristics, management and outcomes of patients taken to hospital by emergency ambulance… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
PURPOSE The Expanded Prostate Cancer Index Composite (EPIC) instrument was designed to assess a range of health-related quality… (More)
Is this relevant?
2017
2017
Objective: To study the difference between intensity-modulated radiation therapy (IMRT) and three dimensional conformal radiation… (More)
Is this relevant?
2016
2016
PURPOSE The new short Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) patient-reported health-related… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2015
2015
OBJECTIVES Currently there are instruments to evaluate the different features of the impact on quality of life in those patients… (More)
Is this relevant?
Review
2015
Review
2015
While there is increasing interest in designing for the developing world, identifying appropriate design research methods for… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
PURPOSE We expanded the clinical usefulness of EPIC-CP (Expanded Prostate Cancer Index Composite for Clinical Practice) by… (More)
  • figure 1
  • figure 2
  • table 1
  • table 3
Is this relevant?
Review
2009
Review
2009
Glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors were developed in the early 1990’s with the purpose of providing maximum platelet… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?